To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination

Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination

GSK has submitted a registration file for its live attenuated oral human rotavirus (HRV) vaccine in several countries. In view of its registration in the Philippines, the present study will collect data on the safety of the vaccine in the local target population as per the Bureau of Food and Drugs Directive.

Study Overview

• Status: Completed
• Conditions: Infections, Rotavirus; Rotavirus Vaccines
• Intervention / Treatment: Biological: Rotarix; Other: Data collection

Detailed Description

The protocol was amended to reflect a change in the prescribing information. The age of the infants was changed from 6 - 14 weeks to at least 6 weeks at the time of the first vaccination. This protocol posting has been amended in order to comply with FDA AA.

• Study Type: Observational
• Enrollment (Actual): 1439

Contacts and Locations

Study Locations

• Philippines
  • Alabang, Muntinlupa City, Philippines, 1780
    • GSK Investigational Site
  • Binangonan, Rizal, Philippines
    • GSK Investigational Site
  • Cainta, Rizal, Philippines
    • GSK Investigational Site
  • Gen. Trias, Cavite, Philippines
    • GSK Investigational Site
  • Imus, Cavite, Philippines
    • GSK Investigational Site
  • Los Banos, Laguna, Philippines, 4027
    • GSK Investigational Site
  • Makati City, Philippines
    • GSK Investigational Site
  • Manila, Philippines, 1000
    • GSK Investigational Site
  • Manila, Philippines
    • GSK Investigational Site
  • Maybunga, Pasig City, Philippines
    • GSK Investigational Site
  • Muntinlupa City, Philippines, 1780
    • GSK Investigational Site
  • Pasay City, Philippines
    • GSK Investigational Site
  • Pasig City, Metro Manila, Philippines, 1600
    • GSK Investigational Site
  • Quezon City, Philippines, 1113
    • GSK Investigational Site
  • Quezon City, Philippines
    • GSK Investigational Site
  • Quezon City, Philippines, 1102
    • GSK Investigational Site
  • Talaba IV, Bacoor, Cavite, Philippines
    • GSK Investigational Site
  • Taytay, Rizal, Philippines
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 5 months (Child)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Filipino subjects aged at least 6 weeks at the time of first vaccination

Description

Inclusion Criteria:

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
• A Filipino male or female aged at least 6 weeks at the time of the first vaccination.
• Written informed consent obtained from the parent or guardian of the subject.

Exclusion Criteria:

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Any history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract.
• Any contraindications as stated in the Prescribing Information.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cohort Group; Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks	Biological: Rotarix; Two doses of the oral vaccine; Other: Data collection; Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects Reporting Grade 2 or 3 Symptoms (Fever, Vomiting or Diarrhea).	Grade 2 or 3 symptoms assessed include fever, vomiting and diarrhea. Grade 2 fever was defined as axillary temperature above 38.0 degrees Celsius (°C) and below or equal to 39.0°C or rectal temperature above 38.5°C and below or equal to 39.5°C. Grade 3 fever was defined as axillary temperature above 39.0°C. Grade 2 vomiting was defined as 2 episodes of vomiting per day. Grade 3 vomiting was defined as at least 3 episodes of vomiting per day. Grade 2 diarrhea was defined as 4-5 looser than normal stools per day. Grade 3 diarrhea was defined as at least 6 looser than normal stools per day.	During the 15-day (Days 0-14) solicited follow-up period after each vaccine dose (Dose 1 and Dose 2).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.	Solicited symptoms assessed included cough, diarrhea, fever, irritability, loss of appetite and vomiting. Any = Any reports of the specified symptom irrespective of intensity grade and relationship to vaccination. Grade 3 symptom: symptom that prevented normal activity. Grade 3 loss of appetite = not eating at all, grade 3 fever = axillary temperature > 39.0°C, grade 3 vomiting = ≥ 3 episodes of vomiting/day and grade 3 diarrhea = ≥ 6 looser than normal stools/day. Related = symptom assessed by the investigator as causally related to the vaccination regardless of intensity grade.	During the 15-day solicited follow-up period (Day 0 to Day 14) after each vaccine dose (Dose 1 and Dose 2).
Number of Subjects Reporting Unsolicited Adverse Events (AE)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.	During the 31-day follow-up period (Day 0 to Day 30) after any vaccine dose.
Number of Subjects Reporting Serious Adverse Events (SAE)	Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.	Throughout the study period (Day 0 to one month post-Dose 2).

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Bravo L, Chitraka A, Liu A, Choudhury J, Kumar K, Berezo L, Cimafranca L, Chatterjee P, Garg P, Siriwardene P, Bernardo R, Mehta S, Balasubramanian S, Karkada N, Htay Han H. Reactogenicity and safety of the human rotavirus vaccine, Rotarix in The Philippines, Sri Lanka, and India: a post-marketing surveillance study. Hum Vaccin Immunother. 2014;10(8):2276-83. doi: 10.4161/hv.29280.

Study record dates

Study Major Dates

• Study Start (Actual): November 16, 2006
• Primary Completion (Actual): March 31, 2010
• Study Completion (Actual): July 17, 2010

Study Registration Dates

• First Submitted: July 17, 2006
• First Submitted That Met QC Criteria: July 17, 2006
• First Posted (Estimate): July 18, 2006

Study Record Updates

• Last Update Posted (Actual): March 16, 2021
• Last Update Submitted That Met QC Criteria: February 23, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: safety; Gastroenteritis; oral; Rotavirus; Filipino; Rotarix; Post-marketing surveillance (PMS); Human Rotavirus (HRV) vaccine
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Reoviridae Infections; Rotavirus Infections
• Other Study ID Numbers: 103366; 2012-004039-21 (EudraCT Number)